'Ozempic penis' could push patients toward risky peptide stacks
Industry Buzz
Currently, there is no scientific evidence that GLP-1 medications such as Ozempic cause an actual increase in penis size. … [W]hen men lose significant weight, particularly in the lower abdomen or pubic area, it can uncover more of the base of the penis that was previously buried in fat.
—Pamela Tambini, MD, via Healthline
Weight loss will often result in improved cardiometabolic health and resultant improved erections due to better blood flow. This can be perceived as improved penile girth.
—Hossein Sadeghi-Nejad, MD, via Verywell Health
Patients are increasingly bringing viral GLP-1 claims into the exam room. One of the newest—and most surprising—is “Ozempic penis.”
Online forums are filled with men claiming their penis appears larger after taking semaglutide or other GLP-1 drugs, with anecdotal reports of gains as large as 1.5 inches circulating online.[] It is the kind of headline-grabbing claim patients are likely to bring into the exam room—not because they expect a lecture on anatomy, but because they want to know whether there’s any truth behind it.
The short answer is no: There is no evidence that GLP-1 receptor agonists enlarge penile tissue. But the phenomenon raises useful opportunities for physicians to discuss body composition, erectile function, cardiometabolic health, and the gap between online hype and clinical reality.
The change may be real, but it is not growth
There is no clinical evidence that semaglutide enlarges penile tissue, and “Ozempic penis” is not a recognized adverse effect in the drug’s prescribing information.[][] Experts instead point to two less sensational explanations.
First, weight loss can reduce the suprapublic fat pad, revealing more of the penile shaft. The penis may look or measure longer without changing anatomically.[]
“Currently, there is no scientific evidence that GLP-1 medications such as Ozempic cause an actual increase in penis size,” Pamela Tambini, MD, an internal medicine and addiction medicine physician, told Healthline.[] “[W]hen men lose significant weight, particularly in the lower abdomen or pubic area, it can uncover more of the base of the penis that was previously buried in fat.”
Second, weight loss can improve blood flow, which may improve erectile quality.[] A firmer erection could be perceived as increased length or girth.
That does not mean every patient’s sexual function improves. In a retrospective study of 3,094 nondiabetic men with obesity, semaglutide use was associated with more new erectile dysfunction diagnoses or phosphodiesterase-5 inhibitor prescriptions than matched controls: 1.47% vs 0.32%.[] Meanwhile, a recent meta-analysis found no statistically significant effect of GLP-1 receptor agonists on erectile dysfunction or testosterone levels.[] For now, the evidence remains limited and mixed.
“Weight loss will often result in improved cardiometabolic health and resultant improved erections due to better blood flow. This can be perceived as improved penile girth,” Hossein Sadeghi-Nejad, MD, a urologist specializing in male infertility and sexual dysfunction at NYU Langone Health, told Verywell Health.[]
Related: 'Ozempic personality' and the psychological toll of GLP-1s‘Ozempic penis’ could fuel risky peptide stacking
For patients thinking, “Ozempic can make my penis bigger? I’ll add it to my peptide stack,” physicians may soon have an awkward—but clinically useful—conversation on their hands.
Semglutide is itself a peptide-based medication, which makes “Ozempic penis” an easy fit for online peptide culture. Commercial clinics now advertise “stacks” combining peptides and other products to target libido, testosterone, erection quality, and sexual performance.[]
The evidence is far less impressive than the marketing. The Sexual Medicine Society of North America notes that peptides proposed for male sexual dysfunction generally lack robust efficacy and safety data.[]
Bremelanotide, or PT-141, is sometimes used off-label for erectile dysfunction, but its only FDA-approved indication is for treating hypoactive sexual desire disorder in premenopausal women—not erectile dysfunction in men.[]
Related: 'My wife is on testosterone. Should I be?' How docs can navigate the surge in male hormone questionsWhat physicians should ask before reassuring patients
Physicians can validate what patients see without validating the explanation circulating online. Weight loss may uncover previously concealed shaft length or improve erection quality, but GLP-1 drugs have not been shown to enlarge genital tissue.
From there, doctors can ask about libido, erection quality, testosterone-related symptoms, cardiometabolic risk, medications, and compounded or gray-market peptide use. New erectile dysfunction, pain, or persistent genital changes should prompt further evaluation.
Related: When GI side effects become a liability risk: How would you manage this Ozempic patient?